Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

Waylivra hits Phase II/III endpoint in FPL
Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said Waylivra volanesorsen cut serum triglyceride levels by 88% vs. 22% for placebo (p<0.001) in patients with familial partial lipodystrophy, meeting the primary endpoint in the Phase II/III BROADEN study. On a secondary endpoint, the antisense inhibitor of APOCIII reduced liver fat by 51.9% vs. 1.5% for placebo (p=0.004). Waylivra is approved in the EU to treat familial chylomicronemia syndrome.

Lynparza extends PFS in Phase III metastatic CRPC study...